HELIX-2, a phase II all-oral combination study of

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 2, 2013 at 7:30 AM

HELIX-2, a phase II all-oral combination study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the treatment of hepatitis C has been initiated

Stockholm, Sweden—Medivir AB (OMX: MVIR), announces that IDENIX has initiated a phase II clinical trial (HELIX-2) evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, samatasvir and TMC647055 with a pharmacokinetic enhancer. The HELIX-2 trial is a 12-week, randomized, open-label study evaluating the efficacy, safety and tolerability of simeprevir, TMC647055 and samatasvir. The trial will evaluate genotype 1 HCV-infected patients who are either treatment -naïve or who have relapsed after prior treatment with interferon and ribavirin. Patients will receive 75 mg of simeprevir, 50 mg samatasvir and 450 mg of TMC647055 plus a low dose of ritonavir as a pharmacokinetic enhancer, each once daily for 12 weeks, with or without the addition of ribavirin. The HELIX-2 trial is the second study in HCV-infected patients to commence under a non-exclusive collaboration agreement between Idenix and Janssen established in January 2013. The HELIX-1 trial of samatasvir in combination with simeprevir was initiated in May 2013 and is ongoing. For additional information about this study, please visit www.clinicaltrials.gov For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Medivir and Janssen R&D Ireland for the treatment of chronic hepatitis C infection in combination with other antivirals in HCV genotype 1 & 4 infected subjects with compensated liver disease, including cirrhosis. Simeprevir was approved for the treatment of genotype 1 hepatitis C in September 2013 in Japan and in the USA and Canada in November. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C. To date, more than 3,700 patients have been treated with simeprevir in clinical trials. About TMC647055 TMC647055 is a potent non-nucleoside hepatitis C polymerase inhibitor with broad genotypic coverage. TMC647055 is in phase II clinical development and is developed by Janssen R&D Ireland to treat chronic hepatitis C virus infections. TMC647055 is being investigated in combination with other DAA agents in all oral interferon-free regimens. There have been no treatment-emergent serious adverse events reported in the program. About Samatasvir (IDX719) Samatasvir is an NS5A inhibitor with low picomolar, pan-genotypic antiviral activity in vitro. To date, samatasvir has been safe and well-tolerated after single and multiple doses of up to 150 mg in healthy volunteers up to 14 days duration, and in HCV-infected patients up to 12 weeks duration. There have been no treatment-emergent serious adverse events reported in the program. Samatasvir has demonstrated potent pan-genotypic antiviral activity in HCV-infected patients with mean maximal viral load reductions up to approximately 4.0 log10 IU/mL across HCV genotypes 1-4 in a proof-of-concept, three-day monotherapy study. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics. For more information about Medivir AB, please visit the Company’s website: www.medivir.com Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people’s health and quality of life.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Industrial Defender Boosts OT Cybersecurity Capabilities

OT Cybersecurity Takes a Step Forward So today, it’s all about this new roll-out by Industrial Defender. Just another tool shedding light in those dim corners of network security for critical infrastructure operators. Honestly, these folks have been at this for quite some time—talking 20 years uphill and still pushing. From Anomalies to Action Their latest magic?...

Sun Pharma's UNLOXCYT Gains NCCN Category 2A Nod

UNLOXCYT: A New Player in Cancer Treatment Well, here's a notch up for Sun Pharma. Their UNLOXCYT® (cosibelimab-ipdl) just got a Category 2A Preferred Designation from the NCCN for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who can't opt for surgery or radiation. And if you know anything about cancer treatment guidelines, you know that's a big...

JELD-WEN CFO Transition: Navigating Finances Amid Changes

Leadership Shake-up at JELD-WEN Alright, folks, the boardroom saga over at JELD-WEN just took another spin. Samantha Stoddard, the brain behind the numbers as Chief Financial Officer, is packing her bags come mid-November. Yeah, she's off to chase new horizons outside the realm of building products, leaving a spot hotter than a New York Stock Exchange ring bell up for...

Shadeform's Spot: Monetizing Idle GPU Resources

Shadeform's Spot Aims To Cut GPU Waste Imagine letting money burn while your GPUs sit in idle mode. That's the reality for many in the cloud computing sector, and Shadeform looks ready to tackle this inefficiency head-on. The launch of Spot, by the GPU Cloud Marketplace Shadeform, offers a novel way to make sure every floating gigaflop translates into some form of...

IBM Backs Leena AI: Shaping Enterprise Automation

IBM's Strategic Bet on Enterprise Automation Diving into the blazing 2026 market, IBM Ventures has thrown its weight behind Leena AI, an enterprise agentic AI firm that's out to shake things up. You see, the name of the game isn't just flashy AI chatbots anymore. Companies like Leena AI are setting their sights on the back-office grunt work—the lifeblood operations in...

Malachi Joe's Memoir Reveals an Untouched History

A Memoir of Profound Historical Reflection Picture a life that starts on forty acres in segregated rural South Carolina. Throw in two tours in Vietnam and several decades of living between these chapters. This isn't some fictional saga; it's the heartbeat of Malachi Joe's new memoir, A Letter from Your Father. Released by Palmetto Publishing, we're looking at a story that...

VIVIFY and ELISIUM Plan Hydrogen-Powered City

Hydrogen Takes Center Stage in Urban Planning Well, I didn't see this one coming—a city that's planning the power before the buildings. We're talking about ELISIUM, the so-called cognitive city destined to rise in Hendry County, Florida. And leading the charge in all this energy planning? None other than VIVIFY Technology, set to bring in its hydrogen expertise right...

Freight Rebound Sparks Strategic M&A Opportunities

Is the Freight Recovery Here to Stay? Just when you thought trucking might have run out of gas, we're hitting a sharp turn back into growth town. For those of you dropping equity crumbs every which way but loose in the last few years, this freight lull has been brutal—like the hangover from hell. But Brown Gibbons Lang & Company’s fresh report now hints at a brighter...

Sarah Weede: A Force in Veterans Services Leadership

Saluting a Veteran's Advocate Amidst a world obsessed with bottom lines and market swings, it’s refreshing to spotlight someone like Sarah R. Weede. She's not about the Wall Street grind but you better believe her drive and dedication rival any big-shot CEO. Leadership in Veterans Services Sarah Weede's story starts with substantial roots planted in serving those who...

Life After Debt: Freedom, Confidence, and Wellbeing

The Unseen Upside of Financial Freedom Debt can feel like a ball and chain, dragging down everything from your sleep to your relationships. But shred that debt, and suddenly the world looks different. Accredited Debt Relief's recent survey of 1,000 folks who've paid off at least $5,000 in unsecured debt uncovers the remarkable transformations that follow. According to 93%...